A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Melanoma Clinical Trial

Official title:

A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02819843
• Other study ID #: 16-224
• Status: Completed
• Phase: Phase 2
• Start date: June 21, 2016
• Est. completion date: February 22, 2024

Study information

• Verified date: April 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: February 22, 2024
• Est. primary completion date: February 22, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Man or woman = 18 years old

• Life expectancy > 4 months

• Histopathologically confirmed melanoma, Merkel cell carcinoma or other solid tumor malignancy

• Cutaneous subcutaneous soft tissue, or superficial lymphatic metastasis not suitable for surgical resection

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

• Cutaneous subcutaneous soft tissue, or superficial lymphatic metastasis that is amenable to injection and irradiation and > 10 mm in longest dimension

° Cutaneous metastasis in a region of previous radiation therapy is amenable to radiation therapy as part of this protocol if at least 6 months has elapsed since prior radiotherapy and the dose of radiotherapy previously administered did not exceed an equivalent dose of 60 Gy in 2 Gy equivalent fractions at the skin surface (using linear-quadratic modeling with alpha/beta=11.5)

• Metastasis that is > 10 mm in longest dimensionor exhibits radiotracer uptake consistent with metastasis on PET/CT

• Adequate coagulation function (platelet count >50 k/mcL, international normalized ratio of < 1.5)

• Resolution or stabilization of clinically significant adverse events from prior therapy

• Able to provide valid written informed consent

Exclusion Criteria:

• Active herpetic skin lesions or prior complications of HSV-1 infection (such as herpetic keratitis, herpetic encephalitis)

• Receipt of a therapeutic anticoagulant

• Receipt of live vaccine within 28 days of planned first dose of TVEC

• Receipt of another cancer therapy (targeted therapy, chemotherapy, investigational therapy, immunotherapy, radiotherapy or surgery) which is yielding an overall response (by response criteria in this study)

° Patients with stable or progressing disease (as determined by at least 2 consecutive assessments at 6-week interval) can continue to receive the same therapy during treatment as part of this protocol

• History of symptomatic autoimmune disease (such as lupus, scleroderma, Crohn's disease, ulcerative colitis) requiring systemic treatment (for example corticosteroids or immunosuppressants); replacement therapy (for example, thyroxine, insulin) is not considered a systemic treatment

• History of high grade (CTCAE = Grade 3) immune mediated adverse event from prior cancer immunotherapy

• History of CTCAE = Grade 2 immune mediated endocrinopathy from prior cancer immunotherapy

• Intermittent or chronic use of oral or intravenous antiherpetic drug (such as acyclovir)

• Active or chronic hepatitis B or C infection

° Previously infected, with evidence of immunity and no evidence of active hepatitis is not an exclusion criterion

• Known human immunodeficiency virus (HIV) infection

• Known leukemia or lymphoma

• Common variable immunodeficiency

• Patients requiring chronic high dose immunosuppressants including steroids (prednisone daily equivalent of = 10 mg)

• Known severe congenital or acquired cellular or humoral immunodeficient or immunocompromised patients

• High likelihood of protocol non-compliance (in opinion of investigator)

• Woman of childbearing potential unwilling to use effective contraception during protocol treatment and for 3 months after last dose of Talimogene Laherparepvec

• Woman of childbearing potential that is pregnant or breast-feeding, or planning to become pregnant or breast-feed during protocol treatment and for 3 months after last dose of Talimogene Laherparepvec

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Merkel Cell
• Melanoma
• Merkel Cell Carcinoma
• Other Solid Tumors

Intervention

Drug:
• TALIMOGENE LAHERPAREPVEC (TVEC)

Radiation:
• Hypofractionated Radiotherapy

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Westchester	Harrison	New York
United States	Memorial Sloan Kettering Monmouth	Middletown	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	response	Overall subject level response is defined as partial or complete (>50% or greater decrease in largest lesion) by the modified World Health Organization (mWHO) criteria, and will include measurements of tumor size by CT component of PET/CT, and clinically by digital photography.	16 weeks

External Links

•   Memorial Sloan Kettering Cancer Center